KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Equity Income (2018 - 2025)

Resmed (RMD) has disclosed Equity Income for 8 consecutive years, with $306000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Income rose 121.26% year-over-year to $306000.0, compared with a TTM value of -$1.8 million through Dec 2025, down 29.23%, and an annual FY2025 reading of $3.6 million, up 190.09% over the prior year.
  • Equity Income was $306000.0 for Q4 2025 at Resmed, up from -$6.2 million in the prior quarter.
  • Across five years, Equity Income topped out at $16.4 million in Q1 2023 and bottomed at -$8.0 million in Q2 2022.
  • Average Equity Income over 5 years is -$670500.0, with a median of -$1.5 million recorded in 2023.
  • The sharpest move saw Equity Income surged 722.73% in 2023, then crashed 742.78% in 2025.
  • Year by year, Equity Income stood at -$1.9 million in 2021, then plummeted by 47.65% to -$2.8 million in 2022, then soared by 33.19% to -$1.9 million in 2023, then increased by 23.78% to -$1.4 million in 2024, then soared by 121.26% to $306000.0 in 2025.
  • Business Quant data shows Equity Income for RMD at $306000.0 in Q4 2025, -$6.2 million in Q3 2025, and $3.8 million in Q2 2025.